

Neurocognitive functioning and brain plasticity in high-grade glioma patients: a magnetoencephalography pilot

Submission date 23/08/2007	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 23/08/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 01/10/2007	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr M. Klein

Contact details
Department of Medical Psychology, D343
Vrije University Medical Centre
Amsterdam
Netherlands
1081 BT
+31 (0)20 444 8432
m.klein@vumc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
NWOpilot01

Study information

Scientific Title

Study objectives

We hypothesise that a relationship is present between functional connectivity, network features and neurocognitive performance in Glioblastoma Multiforme (GBM) patients. We also expect treatment and recurrence of the tumour to lead to remodelling of the neuronosynaptic maps and network features (i.e. plasticity), and hypothesise that these dynamic changes correlate with improvements of cognition.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from ethics boards of two centres participating in the study:

1. Academic Medical Centre (AMC) Medisch Ethische Commissie, received on the 16th July 2007 (ref: MEC 07/134)
2. VU University Medical Center Medical Ethical Board, received on the 12th June 2007 (ref: 2007/108)

Study design

Multicentre, observational, case-control study

Primary study design

Observational

Secondary study design

Case-control study

Study setting(s)

Hospital

Study type(s)

Screening

Participant information sheet

Health condition(s) or problem(s) studied

Glioblastoma multiforme, high grade Glioma

Interventions

Using prospective cognitive data and MEG recordings of ten newly diagnosed glioblastoma multiforme patients and ten glioblastoma multiforme patients with tumour recurrence we will investigate:

1. The impact of tumour- and treatment-related factors on functional connectivity and neural network features, and
2. The correlation between changes in these measures and cognitive function

If such treatment- and/or tumour-related cerebral plasticity and its correlation with cognition can be established in this pilot, future prospective studies will focus in more detail on:

1. The effects of different treatment modalities (e.g. less or more extensive surgery, radiotherapy), and
2. The contribution of tumour-related symptoms (e.g. epilepsy) and their treatment (e.g. anti-epileptic drugs) on neural network function and cognition

This knowledge will eventually assist in the guidance of clinical decision-making in these patients.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Main study parameters are neurocognitive functioning and Magnetoencephalogram (MEG)-measures (synchronisation likelihood and small-world features).

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/09/2007

Completion date

01/06/2008

Eligibility

Key inclusion criteria

For newly diagnosed patients:

1. Adult (greater than 18 years)
2. Radiologically suspected GBM prior to surgery
3. Histologically confirmed GBM after surgery
4. Treatment consisting of surgery followed by combined radiotherapy and chemotherapy
5. Written informed consent

For patients with GBM recurrence:

1. Adult (greater than 18 years)
2. Histologically confirmed GBM
3. Treatment consisting of surgery followed by chemotherapy
4. Written informed consent

For matched healthy controls:

1. Adult (greater than 18 years)
2. Written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Not Specified

Target number of participants

40

Key exclusion criteria

For patient groups:

1. Use of centrally acting drugs, including corticosteroids, other than antiepileptic drugs
2. Psychiatric disease or symptoms
3. Insufficient mastery of the Dutch language
4. Inability to communicate adequately

For controls:

1. Use of centrally acting drugs (including analgesics)
2. Psychiatric disease or symptoms
3. Disorders of the central nervous system
4. Insufficient mastery of the Dutch language

Date of first enrolment

01/09/2007

Date of final enrolment

01/06/2008

Locations**Countries of recruitment**

Netherlands

Study participating centre

Department of Medical Psychology, D343

Amsterdam

Netherlands

1081 BT

Sponsor information**Organisation**

Vrije University Medical Centre (VUMC) (The Netherlands)

Sponsor details

Department of Medical Psychology
Amsterdam
Netherlands
1081 BT

Sponsor type

Hospital/treatment centre

Website

<http://www.vumc.nl/english/>

ROR

<https://ror.org/00q6h8f30>

Funder(s)**Funder type**

Hospital/treatment centre

Funder Name

Vrije University Medical Centre (VUMC) (The Netherlands)

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration